1851 Harbor Bay Parkway
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our three commercially available products, CABOMETYX®(cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. In July 2018, Exelixis was added to the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
619 articles with Exelixis
Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program
ICON-2 program targets Tissue Factor (TF) with potential broad impact in oncology
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following two investor conferences on Tuesday, May 21, 2019, in New York:
First commercial sale triggers $20 million milestone payment to Exelixis
Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma
COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors
Total Revenue of $215.5 Million, Cabozantinib Franchise Revenue of $179.6 Million
Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® (Cabozantinib) for Advanced Renal Cell Carcinoma
Regulatory submission triggers $10 million milestone payment to Exelixis under collaboration and license agreement with Takeda
Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT
Exelixis, Inc. announced that Christopher J. Senner, the company’s Executive Vice President and Chief Financial Officer, and Andrew R. Peters, the company’s Vice President, Strategy, will provide an overview of the company at the 18th Annual Needham Healthcare Conference taking place on Wednesday, April 10, 2019 in New York, NY. The Exelixis presentation is scheduled that day for 4:10 PM EDT / 1:10 PM PDT.
Exelixis, Inc. announced that the company will be presenting at the following investor conferences in March
Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts
Phase 1 dose-escalation trial follows filing of IND in December 2018
Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Cabozantinib Franchise Net Product Revenue of $176.2 million for the Fourth Quarter of 2018, $619.3 million for the Full Year 2018
Exelixis to Present at the Guggenheim Healthcare Talks Idea Forum / Oncology Day 2019 on February 14, 2019
Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Guggenheim Healthcare Talks Idea Forum / Oncology Day taking place on Thursday, February 14, 2019 in New York, NY.
Exelixis to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 12, 2019
Conference Call and Webcast to Follow at 5:00 p.m. EST/ 2:00 p.m. PST
The FDA approved Cabometyx based on the Phase III CELESTIAL trial that showed the drug provided a statistically significant and clinically meaningful improvement in median overall survival.
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial
Because of the government shutdown, which as of Monday, January 14 is into its fourth week, 40 percent of the U.S. FDA employees were furloughed. However, the two approvals described here should still be on track.
Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets for the Treatment of Hypertension in Japan
Exelixis, Inc. announced that its partner Daiichi Sankyo Company, Ltd. received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for esaxerenone tablets, MINNEBRO™ 1.25 mg, 2.5 mg, and 5 mg, as a treatment for patients with hypertension
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma
– Clinical trial will also explore single-agent activity of cabozantinib in the first-line setting –
- Presentations to be webcast on www.exelixis.com -
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib
EC approval triggers $40 million milestone payment to Exelixis under Collaboration Agreement with Ipsen